# A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

> **NCT04275518** · PHASE1 · RECRUITING · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 102 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndromes (MDS)

## Interventions

- **DRUG:** APG-115
- **DRUG:** Azacitidine
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT04275518
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-06
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2024-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04275518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04275518, "A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04275518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*